SHR-A2009 Combined With Bevacizumab in the Treatment of Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer : a Randomized Controlled, Open, Multicenter Phase III Study

Prior treatment

• Anti-tumor therapy such as chemotherapy, biological therapy, targeted therapy, immunotherapy or other unlisted clinical research drugs or treatments were received within 4 weeks before the first medication.
• History of interstitial pneumonia or participants who cannot rule out interstitial pneumonia ; or other moderate to severe lung diseases ; or received previous pneumonectomy surgery
• Have a history of severe bleeding tendency or coagulation dysfunction ; bleeding symptoms with significant clinical significance occurred within 3 months before the first medication.
• Arterial and venous thrombosis events occurred within 6 months before the first administration ;
• Severe infection occurred within 4 weeks before the first administration

Other illness

• Imaging showed that the tumor invaded important organs or tumor surrounding / invasion of large blood vessels or there was obvious necrosis / cavity, which was judged by the researchers to have a risk of bleeding.
• Participants with severe cardiovascular and cerebrovascular diseases
• HIV test positive
• Participants with active hepatitis B or C
• Allergy to any component of the treatment regimen

Other

• Untreated or active central nervous system tumor metastasis

• voluntarily participate in this clinical study, understand the research procedure and be able to sign the informed consent in writing ; the age at the time of signing the informed consent form is 18-75 years old ( including both ends ), both men and women can.
  • The ECOG score was 0 or 1.
• Participants with locally advanced or metastatic non-squamous non-small cell lung cancer confirmed by histology or cytology.
• Adequate bone marrow and organ function.